New Cardioverter-Defibrillator

Parad has been shown to decrease a patient's risk of receiving inappropriate therapy due to AF to only 0.3%.

Ovatio was developed by ELA (Munich, Germany), a Sorin Group company. The first implant was in a 78-year-old man with a history of ischemic cardiomyopathy due to coronary artery disease. Other implants are scheduled to take place in France, Great Britain, Denmark, and the Netherlands. The Ovatio has received the CE mark. Ovatio provides flexible biventricular therapy programming, including ventricle-to-ventricle timing.

"The introduction of Ovatio CRT-D is another illustration of the Sorin Group CRM's commitment to delivering optimal care to the heart failure patient,” remarked Andre-Michel Ballester, president of the Sorin Group's business unit. Sorin Group is a leading developer of medical technologies for cardiac surgery, innovative therapies for cardiac rhythm management, interventional cardiology, and the treatment of chronic kidney diseases.




Related Links:
Sorin